Login Register Cart 0
Generic placeholder image

Anti-Cancer Agents in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1871-5206
ISSN (Online): 1875-5992

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Systematic Review Article

Pralatrexate for Peripheral T-Cell Lymphoma (PTCL): Chance Only Supports The Prepared Mind

Author(s): Serdar Altınay*, Alev Kural, Aykut Özmen, Deniz Tural and Yusuf Tutar

Volume 23, Issue 3, 2023

Published on: 25 August, 2022

Page: [298 - 305] Pages: 8

DOI: 10.2174/1871520622666220610151603

Price: $65

Abstract

Background: Due to their primary effects on DNA synthesis, antimetabolites are most effective against actively dividing cells and are significantly specific to the cell cycle phase. Pralatrexate (PDX), an antifolate metabolite designed to accumulate in cancer cells, was the first new agent approved by the US Food and Drug Administration for the treatment of resistant/recurrent peripheral T-cell lymphomas. PDX was a drug that is frequently used not only for PTCL, but also for cutaneous T-cell lymphoma (CTCL), extranodal natural killer (NK) / T-cell lymphoma.

Objective: This article reviews Pralatrexate's history, pharmacokinetics, clinical phase studies including phases I, II and III, types of cancers it is effective on, drug side effects, inhibition mechanism and even its use in the treatment of other cancers with innovative methods, including its antiviral effect against SARS-CoV-2 infection.

Methods: A comprehensive internet-based research was planned, covering all published and unpublished studies on the subject. We conducted this review in accordance with Preferred Reporting Items for systematic reviews and metaanalysis (PRISMA-P), and Cochrane Collaboration reporting items for systematic reviews and meta-analysis. The results of the studies in the articles were recorded to include all phase studies.

Results: Pralatrexate was structurally designed to have enhanced cellular transport via RFC (reduced folate carrier type) and be subject to more polyglutamation compared to methotrexate. The enhanced polyglutamylation ability of pralatrexate is associated with increased tumor cell death and ultimately improved anticancer activity. Pralatrexate is considered a promising drug for patients with recurrent and treatment-resistant PTCL with a good survival advantage. At the same time, it is an antifolate agent with a significant advantage over methotrexate as it does not cause myelosuppression.

Conclusion: While there are manageable side effects such as thrombocytopenia, neutropenia, and mucositis, it is critical to explore new approaches, targeted agents, novel cellular therapies, and immunotherapies to determine optimal pretreatment in the rare but heterogeneous disease PTCL, and future studies and experienced haematologists are needed.

Keywords: Pralatrexate, lymphoma, oncology, clinical trials, folate, metabolite.

« Previous Next »
[1]
Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F.; Jemal, A.; Bray, F. Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin., 2021, 71(3), 209-249.
[http://dx.doi.org/10.3322/caac.21660] [PMID: 33538338]
[2]
Pratap, S.; Scordino, T.S. Molecular and cellular genetics of non-Hodgkin lymphoma: Diagnostic and prognostic implications. Exp. Mol. Pathol., 2019, 106, 44-51.
[http://dx.doi.org/10.1016/j.yexmp.2018.11.008] [PMID: 30465756]
[3]
Cai, W.; Zeng, Q.; Zhang, X.; Ruan, W. Trends analysis of non-hodgkin lymphoma at the national, regional, and global level, 1990-2019: Results from the global burden of disease study 2019. Front. Med. (Lausanne), 2021, 8(8), 738693.
[http://dx.doi.org/10.3389/fmed.2021.738693] [PMID: 34631756]
[4]
Wang, E.S.; O’Connor, O.; She, Y.; Zelenetz, A.D.; Sirotnak, F.M.; Moore, M.A. Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression. Leuk. Lymphoma, 2003, 44(6), 1027-1035.
[http://dx.doi.org/10.1080/1042819031000077124] [PMID: 12854905]
[5]
Dorigo, A.; Mansberg, R.; Kwan, Y.L. Lomustine, etoposide, methotrexate and prednisone (LEMP) therapy for relapsed and refractory non-Hodgkin’s lymphoma. Eur. J. Haematol., 1993, 50(1), 37-40.
[http://dx.doi.org/10.1111/j.1600-0609.1993.tb00072.x] [PMID: 8436213]
[6]
O’Connor, O.A.; Horwitz, S.; Hamlin, P.; Portlock, C.; Moskowitz, C.H.; Sarasohn, D.; Neylon, E.; Mastrella, J.; Hamelers, R.; Macgregor-Cortelli, B.; Patterson, M.; Seshan, V.E.; Sirotnak, F.; Fleisher, M.; Mould, D.R.; Saunders, M.; Zelenetz, A.D. Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. J. Clin. Oncol., 2009, 27(26), 4357-4364.
[http://dx.doi.org/10.1200/JCO.2008.20.8470] [PMID: 19652067]
[7]
Molina, J.R. Pralatrexate, a dihydrofolate reductase inhibitor for the potential treatment of several malignancies. IDrugs, 2008, 11(7), 508-521.
[PMID: 18600598]
[8]
Kisliuk, R.L. Deaza analogs of folic acid as antitumor agents. Curr. Pharm. Des., 2003, 9(31), 2615-2625.
[http://dx.doi.org/10.2174/1381612033453695] [PMID: 14529545]
[9]
Izbicka, E.; Diaz, A.; Streeper, R.; Wick, M.; Campos, D.; Steffen, R.; Saunders, M. Distinct mechanistic activity profile of pralatrexate in comparison to other antifolates in in vitro and in vivo models of human cancers. Cancer Chemother. Pharmacol., 2009, 64(5), 993-999.
[http://dx.doi.org/10.1007/s00280-009-0954-4] [PMID: 19221750]
[10]
O’Connor, O.A.; Hamlin, P.A.; Portlock, C.; Moskowitz, C.H.; Noy, A.; Straus, D.J.; Macgregor-Cortelli, B.; Neylon, E.; Sarasohn, D.; Dumetrescu, O.; Mould, D.R.; Fleischer, M.; Zelenetz, A.D.; Sirotnak, F.; Horwitz, S. Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma. Br. J. Haematol., 2007, 139(3), 425-428.
[http://dx.doi.org/10.1111/j.1365-2141.2007.06658.x] [PMID: 17910632]
[11]
O’Connor, O.A.; Amengual, J.; Colbourn, D.; Deng, C.; Sawas, A. Pralatrexate: A comprehensive update on pharmacology, clinical activity and strategies to optimize use. Leuk. Lymphoma, 2017, 58(11), 2548-2557.
[http://dx.doi.org/10.1080/10428194.2017.1306642] [PMID: 28738754]
[12]
Memorial sloan kettering cancer center press release. fda approves lymphoma drug developed at memorial sloan kettering. Available from: http://www.mskcc.org/mskcc/html/95988.cfm
[13]
National Cancer Institute. Available from: https://web.archive.org/web/http://www.cancer.gov/ncicancerbulletin/102009/page4
[14]
FDA approves pralatrexate for treatment of peripheral T-cell lymphoma" (Press release). SRI International. 2009. Available from: http://www.sri.com/newsroom/press-releases/fda-approves-pralatrexate
[15]
Food and Drug Administration. Orphan designation pursuant to Section 526 of the Federal Food and Cosmetic Act as amended by the Orphan Drug Act. P.L. , 97-414. Available from: http://www.accessdata.fda.gov/scripts/opdlisting/oopd/index.cfm
[16]
Andrew, Pollack Questioning a cancer drug that costs $30,000 a month. New York Times. Available from: https://www.nytimes.com/2009/12/05/health/05drug.html
[17]
National Library of Medicine (US), National Center for Biotechnology InformationPubChem Compound Summary for CID 148121 Pralatrexate; Bethesda, 2004. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Pralatrexate
[18]
Mould, D.R.; Sweeney, K.; Duffull, S.B.; Neylon, E.; Hamlin, P.; Horwitz, S.; Sirotnak, F.; Fleisher, M.; Saunders, M.E.; O’Connor, O.A. A population pharmacokinetic and pharmacodynamic evaluation of pralatrexate in patients with relapsed or refractory non-Hodgkin’s or Hodgkin’s lymphoma. Clin. Pharmacol. Ther., 2009, 86(2), 190-196.
[http://dx.doi.org/10.1038/clpt.2009.80] [PMID: 19474785]
[19]
Toner, L.E.; Vrhovac, R.; Smith, E.A.; Gardner, J.; Heaney, M.; Gonen, M.; Teruya-Feldstein, J.; Sirotnak, F.; O’Connor, O.A. The schedule-dependent effects of the novel antifolate pralatrexate and gemcitabine are superior to methotrexate and cytarabine in models of human non-Hodgkin’s lymphoma. Clin. Cancer Res., 2006, 12(3 Pt 1), 924-932.
[http://dx.doi.org/10.1158/1078-0432.CCR-05-0331] [PMID: 16467107]
[20]
Advani, R.H.; Ansell, S.M.; Lechowicz, M.J.; Beaven, A.W.; Loberiza, F.; Carson, K.R.; Evens, A.M.; Foss, F.; Horwitz, S.; Pro, B.; Pinter-Brown, L.C.; Smith, S.M.; Shustov, A.R.; Savage, K.J.; Vose, J.M. A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): Final results from the T- cell consortium trial. Br. J. Haematol., 2016, 172(4), 535-544.
[http://dx.doi.org/10.1111/bjh.13855] [PMID: 26627450]
[21]
O’Connor, O.A.; Pro, B.; Pinter-Brown, L.; Bartlett, N.; Popplewell, L.; Coiffier, B.; Lechowicz, M.J.; Savage, K.J.; Shustov, A.R.; Gisselbrecht, C.; Jacobsen, E.; Zinzani, P.L.; Furman, R.; Goy, A.; Haioun, C.; Crump, M.; Zain, J.M.; Hsi, E.; Boyd, A.; Horwitz, S. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: Results from the pivotal PROPEL study. J. Clin. Oncol., 2011, 29(9), 1182-1189.
[http://dx.doi.org/10.1200/JCO.2010.29.9024] [PMID: 21245435]
[22]
Horwitz, S.M.; Kim, Y.H.; Foss, F.; Zain, J.M.; Myskowski, P.L.; Lechowicz, M.J.; Fisher, D.C.; Shustov, A.R.; Bartlett, N.L.; Delioukina, M.L.; Koutsoukos, T.; Saunders, M.E.; O’Connor, O.A.; Duvic, M. Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood, 2012, 119(18), 4115-4122.
[http://dx.doi.org/10.1182/blood-2011-11-390211] [PMID: 22394596]
[23]
Bhurani, M.; Admojo, L.; Van Der Weyden, C.; Twigger, R.; Bazargan, A.; Quach, H.; Zimet, A.; Coyle, L.; Lindsay, J.; Radeski, D.; Hawkes, E.; Kennedy, G.; Irving, I.; Gutta, N.; Trotman, J.; Yeung, J.; Dunlop, L.; Hua, M.; Giri, P.; Yuen, S.; Panicker, S.; Moreton, S.; Khoo, L.; Scott, A.; Kipp, D.; McQuillan, A.; McCormack, C.; Dickinson, M.; Prince, H.M. Pralatrexate in relapsed/refractory T-cell lymphoma: A retrospective multicenter study. Leuk. Lymphoma, 2021, 62(2), 330-336.
[http://dx.doi.org/10.1080/10428194.2020.1827241] [PMID: 33026266]
[24]
Sugaya, M.; Hamada, T.; Kawai, K.; Yonekura, K.; Ohtsuka, M.; Shimauchi, T.; Tokura, Y.; Nozaki, K.; Izutsu, K.; Suzuki, R.; Setoyama, M.; Nagatani, T.; Koga, H.; Tani, M.; Iwatsuki, K. Guidelines for the management of cutaneous lymphomas (2011): A consensus statement by the Japanese Skin Cancer Society - Lymphoma Study Group. J. Dermatol., 2013, 40(1), 2-14.
[http://dx.doi.org/10.1111/j.1346-8138.2012.01639.x] [PMID: 22900999]
[25]
Kamijo, H.; Miyagaki, T. Mycosis fungoides and sézary syndrome: Updates and review of current therapy. Curr. Treat. Options Oncol., 2002, 22(2), 10.
[26]
Swerdlow, S.H.; Campo, E.; Swerdlow, S.H.; Pileri, S.A.; Harris, N.L.; Stein, H.; Siebert, R.; Advani, R.; Ghielmini, M.; Salles, G.A.; Zelenetz, A.D.; Jaffe, E.S. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood, 2016, 127(20), 2375-2390.
[27]
Yamaguchi, M.; Kwong, Y.L.; Kim, W.S.; Maeda, Y.; Hashimoto, C.; Suh, C.; Izutsu, K.; Ishida, F.; Isobe, Y.; Sueoka, E.; Suzumiya, J.; Kodama, T.; Kimura, H.; Hyo, R.; Nakamura, S.; Oshimi, K.; Suzuki, R. Phase II study of smile chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: The NK-Cell Tumor Study Group study. J. Clin. Oncol., 2011, 29(33), 4410-4416.
[28]
Kim, S.J.; Kim, J.H.; Ki, C.S.; Ko, Y.H.; Kim, J.S.; Kim, W.S. Epstein-Barr virus reactivation in extranodal natural killer/T-cell lymphoma patients: A previously unrecognized serious adverse event in a pilot study with romidepsin. Ann. Oncol., 2016, 27(3), 508-513.
[http://dx.doi.org/10.1093/annonc/mdv596] [PMID: 26658891]
[29]
Liu, Y.C.; Lin, T.A.; Wang, H.Y.; Ko, P.S.; Liu, C.J.; Hsiao, L.T.; Chien, S.H.; Gau, J.P. Pralatrexate as a bridge to allogeneic hematopoietic stem cell transplantation in a patient with advanced-stage extranodal nasal-type natural killer/T cell lymphoma refractory to first-line chemotherapy: A case report. J. Med. Case Rep., 2020, 14(1), 43.
[30]
Folotyn prescribing information; Acrotech Biopharma LLC: East Windsor, 2020. Available from: http://www.folotyn.com/wp-content/uploads/2019/11/Folotyn-PI-09- 2020-REF-0255.pdf
[31]
Wang, X.; Wang, H.; Song, Y. Clinical efficacy and mechanism of Pralatrexate combined with Palbociclib Isethionate in treatment of bladder cancer patients. Oncol. Lett., 2019, 17(1), 201-208.
[PMID: 30655756]
[32]
Malhotra, U.; Mukherjee, S.; Fountzilas, C.; Boland, P.; Miller, A.; Patnaik, S.; Attwood, K.; Yendamuri, S.; Adjei, A.; Kannisto, E.; Opyrchal, M.; Bushunow, P.; Loud, P.; Iyer, R.; Khushalani, N. Pralatrexate in combination with oxaliplatin in advanced esophagogastric cancer: A phase II trial with predictive molecular correlates. Mol. Cancer Ther., 2020, 19(1), 304-311.
[http://dx.doi.org/10.1158/1535-7163.MCT-19-0240] [PMID: 31575653]
[33]
Clark, R.A.; Lee, S.; Qiao, J.; Chung, D.H. Preclinical evaluation of the anti-tumor activity of pralatrexate in high-risk neuroblastoma cells. Oncotarget, 2020, 11(32), 3069-3077.
[http://dx.doi.org/10.18632/oncotarget.27697] [PMID: 32850011]
[34]
Henderson, Y.C.; Mohamed, A.S.R.; Maniakas, A.; Chen, Y.; Powell, R.T.; Peng, S.; Cardenas, M.; Williams, M.D.; Bell, D.; Zafereo, M.E.; Wang, R.J.; Scherer, S.E.; Wheeler, D.A.; Cabanillas, M.E.; Hofmann, M.C.; Johnson, F.M.; Stephan, C.C.; Sandulache, V.; Lai, S.Y. A High-throughput approach to identify effective systemic agents for the treatment of anaplastic thyroid carcinoma. J. Clin. Endocrinol. Metab., 2021, 106(10), 2962-2978.
[http://dx.doi.org/10.1210/clinem/dgab424] [PMID: 34120183]
[35]
Bae, J.Y.; Lee, G.E.; Park, H.; Cho, J.; Kim, J.; Lee, J.; Kim, K.; Kim, J.I.; Park, M.S. Antiviral efficacy of pralatrexate against SARS-CoV-2. Biomol. Ther. (Seoul), 2021, 29(3), 268-272.

Rights & Permissions Print Cite
Article Metrics
6
© 2024 Bentham Science Publishers | Privacy Policy